Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 617 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Wine Racks and the Mystery of Survival September 16, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor February 3, 2021 Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 New on NCI’s Websites, March 2020 March 16, 2020 Load more HOT NEWS Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... New Task Force Focuses on Quality of Life for AYAs with... Quitting Smoking Improves Survival in People with Lung Cancer Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared...
